Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe
5/11/2012 10:33:44 AM
FLEMINGTON, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (OTCBB: ARNI) announced today that its investigational compound known as AR-42 has been granted orphan-drug designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products for the treatment of neurofibromatosis type 2 (NF2). NF2 is a rare genetic disorder characterized by the growth of noncancerous tumors in the brain and spinal cord, juvenile cataracts and neurofibromas of the skin. The disease is caused by mutations in a gene which plays a role in preventing cells from dividing uncontrollably.